A clinical trial of a potential remyelinating drug in multiple sclerosis.


  • Multiple sclerosis

Project type

  • Clinical drug trial

About the project

The "CCMR One" clinical trial is a randomised double blind placebo controlled study. The purpose of this clinical research study is to assess whether bexarotene can promote remyelination.

Nerves within the brain and spinal cord are protected by a surrounding layer of substance called myelin. In multiple sclerosis (MS), the immune system of the body attacks this myelin, stripping it off the nerve fibres. This causes the nerves to malfunction, leading to multiple sclerosis symptoms. Studies have shown that a group of drugs can stimulate cells in the brain to repair damaged myelin. This process is called 'remyelination'. One of the drugs in this group is bexarotene, a capsule already used as an anti-cancer medication. We think that bexarotene may also promote remyelination in people with MS who are also taking disease-modifying drugs and also to assess whether it really can promote remyelination.

Participants in the trial take several capsules (which might be bexarotene or a placebo) a day for 6 months and remyelination is assessed by one MRI scan at the beginning of this six-month period and one at the end.

More information

CCMR One on the EU Clinical Trials Register


Anne Rowling Clinic, Chief Scientist Office and MS Society



Closed – analysing data


Dawn Lyle, Research Project Coordinator
0131 465-9517

Eligibility criteria

Study participants need to live reasonably close to the Anne Rowling Clinic as frequent visiting (at times weekly) is required. Participants should have a diagnosis of relapsing-remitting multiple sclerosis (RRMS), need to be able to walk, and should be taking a first-line disease-modifying drug (beta-interferon, copaxone, Tecfidera etc). Other criteria also apply.